Elicio Therapeutics, Inc.
ELTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $28 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | -$1 | -$1 | -$1 | $27 |
| % Margin | – | – | – | 95.6% |
| R&D Expenses | $34 | $23 | $17 | $49 |
| G&A Expenses | $11 | $12 | $0 | $0 |
| SG&A Expenses | $11 | $12 | $6 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $44 | $35 | $23 | $66 |
| Operating Income | -$45 | -$36 | -$24 | -$39 |
| % Margin | – | – | – | -138.8% |
| Other Income/Exp. Net | -$7 | $1 | -$4 | -$15 |
| Pre-Tax Income | -$52 | -$35 | -$28 | -$55 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$52 | -$35 | -$28 | -$26 |
| % Margin | – | – | – | -93.2% |
| EPS | -4.25 | -6.96 | -9.1 | -19.32 |
| % Growth | 38.9% | 23.5% | 52.9% | – |
| EPS Diluted | -4.25 | -6.96 | -9.1 | -19.32 |
| Weighted Avg Shares Out | 12 | 5 | 3 | 3 |
| Weighted Avg Shares Out Dil | 12 | 5 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $4 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$50 | -$33 | -$24 | -$52 |
| % Margin | – | – | – | -183.4% |